Cosciens Biopharma's revenue for the
three
months ended in Mar. 2026 was $1.89 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $7.89 Mil.
Cosciens Biopharma's Revenue per Share for the
three
months ended in Mar. 2026 was $0.51.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.40.
Warning Sign:
Cosciens Biopharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Cosciens Biopharma was -25.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -32.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -18.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -4.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Cosciens Biopharma's highest 3-Year average Revenue per Share Growth Rate was 51.30% per year. The lowest was -36.00% per year. And the median was 7.30% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Cosciens Biopharma Revenue Related Terms
Cosciens Biopharma Revenue Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cosciens Biopharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Revenue distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCIF) has a Revenue of $7.89 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Cosciens Biopharma and its competitors.
Is Cosciens Biopharma's Revenue too high?
Cosciens Biopharma's current Revenue is $7.89 Mil. Overall, Cosciens Biopharma has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Revenue compare to VRTX and REGN?
Cosciens Biopharma's Revenue of $7.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Revenue is $7.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.38, compared to a current price of $2.15 — trading 9.7% below its estimated fair value. The current Revenue is $7.89 Mil. Cosciens Biopharma's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Revenue is $7.89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $2.15 is trading 9.7% below its estimated GF Value™ of $2.38.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
Revenue: $7.89 Mil
GF Value™: $2.38 vs. price of $2.15 (9.7% below fair value)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
60GF Score
Get the complete analysis for CSCIF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
